Sarah Makram Elsayed

Sarah Makram Elsayed

Auto-generated profile, based on publicly available information

Sarah Makram Elsayed

Pediatrics Department, National Heart Institute, Giza, Egypt

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Indian Heart Journal
Verified
Journal Article
Open access
FAFadel Alqatati
Fadel Alqatati
MEMohammad Elbahnasawy
Mohammad Elbahnasawy
SBSeif Bugazia
Seif Bugazia
KRKhaled Mohamed Ragab
Khaled Mohamed Ragab
AEAhmed Bostamy Elsnhory
Ahmed Bostamy Elsnhory
ANAnas Nourelden
Anas Nourelden
To assess the safety and efficacy of omecamtiv mecarbil compared with placebo in heart failure (HF) patients. We searched PubMed, Web of Science, Cochrane Library, and SCOPUS until August 15th, 2021. We included all randomized controlled studies comparing omecamtiv mecarbil with placebo in heart failure patients. The meta-analysis was carried out using Rev Man software V5.4. A total of eight studies were included in our systematic review. Pooled analysis showed that omecamtiv mecarbil is not associated with increased incidence of death, any adverse events, hypotension, heart failure, ventricular tachyarrhythmia, dyspnea, dizziness, and serious adverse events. Regarding the efficacy, omecamtiv mecarbil significantly reduced heart rate with some studies demonstrating its significant improvement in left ventricular ejection fraction and systolic function. Conclusion: Omecamtiv mecarbil is a well-tolerated drug in heart failure patients. The limited data regarding the efficacy suggested that it may improve ejection fraction and systolic function.

23 October 2025 in International Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
COChibuike Daniel Onyejesi
Chibuike Daniel Onyejesi
SESarah Makram Elsayed
Sarah Makram Elsayed
JIJohn Magdy Daniel Isaac
John Magdy Daniel Isaac
EAEslam Moumen Abady
Eslam Moumen Abady
WSWafaa Shehada
Wafaa Shehada
MAMohammed Alsabri
Mohammed Alsabri
Pediatric emergency departments (PEDs) are high-risk environments where patient injury can result from delays, unclear diagnoses, and poor communication. Quality improvement (QI) and safety culture initiatives are increasingly being used to improve outcomes, but their interaction in PEDs remains underexplored. This systematic review and meta-analysis evaluated how safety culture and QI initiatives impact clinical and functional outcomes in PEDs. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Cochrane, Scopus, and Web of Science through December 2024. We included 31 studies, most of which used pre/post designs; one was a randomized controlled trial. Most interventions aimed to improve care in PEDs by focusing on protocol standardization, safety checklists, simulation-based training and leadership engagement tailored to the pediatric emergency department (PED) setting. Meta-analyses showed a significant decrease in unnecessary radiation exposure (6.45%-20.55%; p<0.0001) and PED length of stay (LOS) (~25 minutes; p<0.05). Additional findings included decreased healthcare expenses, unnecessary interventions, and better patient flow. Most studies were at moderate risk of bias across the assessed domains with ROBINS-I tool. . These findings suggest that QI techniques can significantly improve the quality and efficiency of care when supported by a strong safety culture. These results show how essential it is to bring together both practical processes and cultural changes to build reliable, lasting systems that truly meet the unique needs of PEDs.

1 August 2023 in Current Women s Health Reviews
Verified
Journal Article
Closed access
PDF file
SBSeif Bugazia
Seif Bugazia
MBMohamed Boshnaf
Mohamed Boshnaf
MEMohammad Elbahnasawy
Mohammad Elbahnasawy
MSMostafa Shehata
Mostafa Shehata
FAFadel Alqatati
Fadel Alqatati
ANAnas Nourelden
Anas Nourelden
Background and objectives: Diabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women. Methods: We searched four electronic databases until August 2021: PubMed, Scopus, Web of Science, and Cochrane. We included randomized controlled studies that compared IDet with NPH in diabetic pregnant women. We extracted both maternal and neonatal outcomes, and used RevMan software to conduct the analysis. Results: A number of five studies were included. The analysis showed a significantly lower risk of hypoglycemic events during pregnancy in the IDet group than the NPH group [RR=0.6, 95% CI [0.43, 0.84], p=0.003], and a higher gestational age (GA) at delivery in the IDet group than the NPH group [MD= 0.28, 95% [0.02, 0.55], p=0.03]. On the other hand, the analysis revealed non-significant differences between IDet and NPH in terms of birth weight, congenital anomalies, neonatal hypoglycemia, preterm delivery, and others. Conclusion: Insulin detemir (IDet) was preferred over neutral protamine Hagedorn (NPH) in terms of showing lower rates of hypoglycemic events during pregnancy and a higher gestational age at delivery. Meanwhile, there were non-significant variations between them when it comes to neonatal outcomes, such as weight at birth, congenital anomalies, or neonatal hypoglycemia.